The Power of Three: Helios Bioelectronics, GattaCo, and iAssay Unite to Clobber Infectious Disease
The Californer/10142392

SAN DIEGO - Californer -- From Athos, Porthos, and Aramis to Luke, Leia, and Han, something magical happens when three forces unite.

Today, a trio of cutting-edge companies announced a global collaboration that will enable nearly instant medical test results, bypassing traditional biological laboratories and forwarding critical data to doctors, hospitals and  health agencies.

"From COVID-19 to leukemia, patients and clinicians need fast and accurate diagnoses," said Lonnie Adelman, CEO of San Diego's iAssay. "This collaboration will revolutionize how scientific and medical data is produced, collected, and shared."

The techniques pioneered by these three companies – iAssay of San Diego, Calif.; GattaCo of Murrieta, Calif.; and Taiwan's Helios Bioelectronics – can be used by engineers as well as medical professionals.  Besides medical and scientific applications, soil or water samples,could be tested for toxins, minerals or other materials.

More on The Californer

• Top 10 AI Trading Agents Hit 75% Annual Return for Retail Traders (BP, CNQ, EQNR, WMB, VLO, MPC, OXY)
• Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
• Flow Opens Its Judgment Layer to Every Company Deploying AI Agents
• Mountzo Launches TV Mounting in Sacramento, Expanding Nationwide
• Thursday's Hair Solutions Announces Online Booking Option to Schedule Free Consultations

"By using many strands," said Dr. Hardy Chan, CEO of Helios, "we are weaving a stronger rope."

Helios Bioelectronics is the developer of a multi-patented electrochemical chip, the FET Chip, which identifies targeted elements such as viral proteins or nucleic acids that can be used to identify diseases such as COVID-19. Sometimes called "lab on a chip," this nanotechnology enables a vast amount of information to be gathered through assays processed at the point-of-care that would otherwise rely on detection via laboratories.

Using its patented sample purification technology, GattaCo has developed a plasma separation tool, the A-PON™. The A-PON automatically separates plasma from whole blood collected from a finger-stick without needing a centrifuge. GattaCo is developing a blood analysis cartridge system that integrates its sample purification technology together with Helios Bioelectronics' FET Chip. This cartridge will be read by iAssay's SimpleTest™ base technology with an adaptor specifically developed for the Helios/GattaCo cartridge.

More on The Californer

• Gallagher Domanski PLC Announces Multiple Recent EB-2 NIW Approvals Across STEM & Infrastructure
• Keep Your Eyes To The Sky…We Up !
• Trade Course Hub Expands Online Library of Trading Courses and Education
• ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
• California: Governor Newsom announces appointments

iAssay's patented SimpleTest™ automatically interprets test and control indications on a variety of medical tests.  After SimpleTest™ produces a test result, the device transmits the results to the company's SimpleCloud™, where results can be viewed in a password protected portal by doctors, hospitals, state and federal agencies, or scientists for research.

"This partnership has the potential of saving time, yes, but also saving lives," said Dr. Michael McNeely, president of GattaCo. "Knowledge is power, and the sooner patients and their doctors understand what they are dealing with, the sooner they can seek the correct treatment."

"Health and safety are universal needs," said Helios' Chan. "We may be on the other side of the world from our California partners, but we stand shoulder-to-shoulder with them in this essential work."

Visit http://www.iassay.net for details.
Visit http://www.gattaco.com for details.
Visit heliosbioelectronics.com for details.